ATE329912T1 - (imidazol-1-yl-methyl)pyridazin als nmda- rezeptorblocker - Google Patents

(imidazol-1-yl-methyl)pyridazin als nmda- rezeptorblocker

Info

Publication number
ATE329912T1
ATE329912T1 AT03752750T AT03752750T ATE329912T1 AT E329912 T1 ATE329912 T1 AT E329912T1 AT 03752750 T AT03752750 T AT 03752750T AT 03752750 T AT03752750 T AT 03752750T AT E329912 T1 ATE329912 T1 AT E329912T1
Authority
AT
Austria
Prior art keywords
pyridazine
imidazole
methyl
nmda receptor
receptor blocker
Prior art date
Application number
AT03752750T
Other languages
English (en)
Inventor
Bernd Buettelmann
Neidhart Marie-Paule Heitz
Georg Jaeschke
Emmanuel Pinard
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE329912T1 publication Critical patent/ATE329912T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT03752750T 2002-05-16 2003-05-16 (imidazol-1-yl-methyl)pyridazin als nmda- rezeptorblocker ATE329912T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02010217 2002-05-16

Publications (1)

Publication Number Publication Date
ATE329912T1 true ATE329912T1 (de) 2006-07-15

Family

ID=29433072

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03752750T ATE329912T1 (de) 2002-05-16 2003-05-16 (imidazol-1-yl-methyl)pyridazin als nmda- rezeptorblocker

Country Status (31)

Country Link
US (1) US7005432B2 (de)
EP (1) EP1506190B1 (de)
JP (1) JP4267569B2 (de)
KR (1) KR100632868B1 (de)
CN (1) CN1312151C (de)
AR (1) AR040010A1 (de)
AT (1) ATE329912T1 (de)
AU (1) AU2003242542B2 (de)
BR (1) BR0311177A (de)
CA (1) CA2485926C (de)
CL (1) CL2004001251A1 (de)
CY (1) CY1105159T1 (de)
DE (1) DE60306152T2 (de)
DK (1) DK1506190T3 (de)
ES (1) ES2265581T3 (de)
HK (1) HK1080845A1 (de)
HR (1) HRP20041060B1 (de)
IL (1) IL164922A (de)
MA (1) MA27117A1 (de)
ME (1) MEP76708A (de)
MX (1) MXPA04011253A (de)
NO (1) NO329605B1 (de)
NZ (1) NZ536310A (de)
PL (1) PL211340B1 (de)
PT (1) PT1506190E (de)
RS (1) RS51200B (de)
RU (1) RU2317294C2 (de)
SI (1) SI1506190T1 (de)
TN (1) TNSN04224A1 (de)
WO (1) WO2003097637A1 (de)
ZA (1) ZA200408789B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
GB0218876D0 (en) * 2002-08-13 2002-09-25 Merck Sharp & Dohme Therapeutic agents
CN100579579C (zh) * 2002-10-01 2010-01-13 诺华疫苗和诊断公司 抗癌及抗感染性疾病组合物及其使用方法
CN101171320B (zh) * 2005-05-03 2013-04-10 默克专利有限公司 有机电致发光器件
US20090054392A1 (en) * 2007-08-20 2009-02-26 Wyeth Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
JP5315710B2 (ja) * 2008-02-07 2013-10-16 セントラル硝子株式会社 1−ブロモ−3−フルオロ−5−ジフルオロメチルベンゼンの製造方法
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
BRPI0909378A2 (pt) * 2008-03-27 2015-10-06 Evotec Neurosciences Gmbh métodos para tratar distúrbios usando antagonista seletivo de nmda subtipo nr2b
MY170610A (en) 2009-02-05 2019-08-20 Takeda Pharmaceuticals Co Pyridazinone compounds
JP5785548B2 (ja) * 2010-08-04 2015-09-30 武田薬品工業株式会社 縮合複素環化合物
WO2012019106A2 (en) * 2010-08-06 2012-02-09 Board Of Regents Of The University Of Nebraska Positive and negative modulators of nmda receptors
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
DK3180329T3 (da) * 2014-08-15 2020-04-06 Janssen Pharmaceuticals Inc Triazoler som nr2b receptorinhibitorer
MX2018009752A (es) 2016-02-10 2019-02-07 Janssen Pharmaceutica Nv 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b.
WO2017140771A1 (en) 2016-02-18 2017-08-24 Syngenta Participations Ag Pesticidally active pyrazole derivatives
WO2017158151A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2017158147A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途
JP7332472B2 (ja) 2016-12-22 2023-08-23 ノバルティス アーゲー Nmda受容体モジュレーターおよびその使用
WO2019193516A2 (en) 2018-04-04 2019-10-10 Janssen Pharmaceutica Nv Substituted pyridine and pyrimidines and their use as glun2b receptor modulators
JP7319369B2 (ja) 2018-08-03 2023-08-01 ノバルティス アーゲー ヘテロ芳香族nmda受容体モジュレーターおよびその使用
CA3143105A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators
AU2020293584A1 (en) 2019-06-14 2022-01-20 Janssen Pharmaceutica Nv Pyridine carbamates and their use as GluN2B receptor modulators
EP3983072A1 (de) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Pyrazincarbamate und ihre verwendung als glun2b-rezeptor-modulatoren
CR20210615A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Pirazolo piridinas heteroaromáticas sustituidas y su uso como moduladores del receptor glun2b
PE20220386A1 (es) 2019-06-14 2022-03-18 Janssen Pharmaceutica Nv Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b
JP2022536174A (ja) 2019-06-14 2022-08-12 ヤンセン ファーマシューティカ エヌ.ベー. 置換ピラゾロ[4,3-b]ピリジニル及びGLUN2B受容体調節因子としてのそれらの使用
CN114478210A (zh) * 2022-02-26 2022-05-13 江苏壹药新材料有限公司 一种7-氯萘-2-甲醛的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT885004E (pt) * 1996-03-08 2002-08-30 Hoffmann La Roche Utilizacao de derivados de 4-fenil-3,6-di-hidro-2h-piridilo como bloqueadores dos subtipos dos receptores nmda
CA2220649C (en) * 1996-12-03 2007-02-13 F. Hoffmann-La Roche Ag 4-hydroxy-piperidine derivatives
US6015824A (en) 1998-02-10 2000-01-18 Hoffmann-La Roche Ag Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders
TWI254043B (en) * 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor
DE60007697T2 (de) * 1999-07-21 2004-12-09 F. Hoffmann-La Roche Ag Triazolderivate
US6339093B1 (en) * 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives
EP1278728B1 (de) * 2000-04-20 2004-08-25 F. Hoffmann-La Roche Ag Pyrrolidin und piperidin derivate für die behandlung von neurodegenerativen erkrankungen
US6432985B2 (en) * 2000-04-25 2002-08-13 Hoffmann-La Roche Inc. Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists
WO2002028814A2 (en) 2000-10-06 2002-04-11 Regents Of The University Of California Nmda receptor channel blocker with neuroprotective activity
CA2381630A1 (en) 2001-04-23 2002-10-23 Leonard Theodore Meltzer Method for preventing dyskinesias
DE10120159A1 (de) 2001-04-25 2002-10-31 Merck Patent Gmbh NMDA-Antagonisten und NMDA-Agonisten zur Behandlung von Suchterkrankungen
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives

Also Published As

Publication number Publication date
NZ536310A (en) 2007-08-31
MA27117A1 (fr) 2004-12-20
CY1105159T1 (el) 2009-11-04
PL374224A1 (en) 2005-10-03
RU2317294C2 (ru) 2008-02-20
IL164922A (en) 2012-01-31
EP1506190A1 (de) 2005-02-16
CA2485926C (en) 2009-11-24
NO329605B1 (no) 2010-11-22
DK1506190T3 (da) 2006-10-16
BR0311177A (pt) 2005-03-15
WO2003097637A1 (en) 2003-11-27
US7005432B2 (en) 2006-02-28
CN1653062A (zh) 2005-08-10
AU2003242542B2 (en) 2008-10-16
TNSN04224A1 (fr) 2007-03-12
RS51200B (sr) 2010-12-31
JP4267569B2 (ja) 2009-05-27
HRP20041060B1 (en) 2012-11-30
RU2004136979A (ru) 2005-07-10
JP2005532326A (ja) 2005-10-27
RS98504A (en) 2006-12-15
DE60306152D1 (de) 2006-07-27
CL2004001251A1 (es) 2005-04-22
NO20044666L (no) 2004-12-15
EP1506190B1 (de) 2006-06-14
AR040010A1 (es) 2005-03-09
CA2485926A1 (en) 2003-11-27
HRP20041060A2 (en) 2005-06-30
SI1506190T1 (sl) 2006-10-31
KR100632868B1 (ko) 2006-10-13
CN1312151C (zh) 2007-04-25
ZA200408789B (en) 2005-12-28
HK1080845A1 (en) 2006-05-04
IL164922A0 (en) 2005-12-18
PT1506190E (pt) 2006-11-30
AU2003242542A1 (en) 2003-12-02
PL211340B1 (pl) 2012-05-31
US20030229096A1 (en) 2003-12-11
MEP76708A (en) 2011-12-20
KR20040106558A (ko) 2004-12-17
MXPA04011253A (es) 2005-01-25
DE60306152T2 (de) 2007-04-26
ES2265581T3 (es) 2007-02-16

Similar Documents

Publication Publication Date Title
ATE329912T1 (de) (imidazol-1-yl-methyl)pyridazin als nmda- rezeptorblocker
DE50304867D1 (en) Thiazolderivate als phosphodiesterase iv-inhibtoren
ATE384053T1 (de) Triazolderivate als tachykininrezeptor- antagonisten
DE60326436D1 (en) Aminoderivate als histone-deacetylase-inhibitoren
DE60321207D1 (en) Diaryläther als opioid-rezeptor antagonisten
PL379420A1 (pl) Pochodne blokerów receptora angiotensyny II
AU2002353081A1 (en) Pulsatile release histamine h2 antagonist dosage forms
AU2003298273A1 (en) Chromatography system
DE60122495D1 (de) TRANS-N-i4-(4-HYDROXYPHENYL)CYCLOHEXYLö-3-PHENYLPROPIONAMID ALS SUBTYP-SELEKTIVER NMDA REZEPTOR ANTAGONIST
DE602004017438D1 (de) Biarylsubstituierte triazole als natriumkanalblocker
WO2005046122A8 (en) Computer network
AU2003257032A1 (en) Antibodies against c3a receptor
DE60306540D1 (en) Cyclopropylthienylcarbonsäureamide als fungizide
EP1721414A4 (de) Netzwerkarchitektur
DE60319410D1 (en) Chinazolinderivate als src-tyrosinkinaseinhibitoren
EP1758302A4 (de) Netzwerksystem
AU2003226395A1 (en) Network processor architecture
AU2003295566A8 (en) Fault-tolerant multicasting network
AU2003245259A1 (en) Substituted imidazole derivatives: gabaa receptor ligands
AU2002255355A1 (en) Mechanism for fixing network apparatus
AU2003268770A1 (en) Sustained release preparation containing nk4
AU2002241284A1 (en) Network telephone system
AU2003248251A1 (en) Exposure system
TW536115U (en) Structure for fixing network accessories
AU2004903338A0 (en) User Interface for Workflow System

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1506190

Country of ref document: EP